Osiris Therapeutics Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Stryker (SYK) Announces Receipt of FDA 510(k) Clearance for Mako
August 6, 2015 3:11 PM EDTStryker (NYSE: SYK) announced that its 510(k) submission for the Mako total knee application has received market clearance by the U.S. Food and Drug Administration.
This clearance expands Stryker's current Mako offering of partial knee and total hip applications to provide a comprehensive... More
Osiris Therapeutics (OSIR) PT Raised to $25 at Brean Capital; Grafix Positioned Well for Accelerated Growth
August 6, 2015 8:26 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and raised the price target on Osiris Therapeutics (NASDAQ: OSIR) to $25.00 (from $19.00), saying Grafix is positioned well for accelerated growth.
Yang commented, "Q2 met expectations on revenue but missed on... More
Osiris Therapeutics (OSIR) Misses Q2 EPS by 3c
August 5, 2015 9:09 AM EDTOsiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of $0.03, $0.03 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.6 million.
We remain laser focused on growing revenue and investing in our leading brands, said Lode... More
